University of Wisconsin–Madison

Running trials

• Not yet recruiting

  Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT

  NCT07909733· Phase 1· University of Wisconsin, Madison· Source

• Not yet recruiting

  LDRT Retreatment for Knee Osteoarthritis

  NCT07933523· Phase 2· University of Wisconsin, Madison· Source

• Not yet recruiting

  PSMA PET/MRI for Predicting and Detecting Prostate Cancer

  NCT07924605· Phase 2· University of Wisconsin, Madison· Source

• Recruiting

  Allogeneic iNKT Cell Therapy (agenT-797) After SCT

  NCT07758218· Phase 1· University of Wisconsin, Madison· Source

• Recruiting

  A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)

  NCT07416552· Phase 1· Hoffmann-La Roche· Source

• Recruiting

  Neuro-MoD: Neuroplasticity With Motor Development

  NCT07738432· University of Wisconsin, Madison· Source

• Not yet recruiting

  Letermovir for R+ Study

  NCT07706166· Phase 4· University of Wisconsin, Madison· Source

• Not yet recruiting

  Improving the Quality of Care for Asthma Patients at Risk of Exacerbations

  NCT06596512· Brigham and Women's Hospital· Source

• Recruiting

  A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy

  NCT07675135· Phase 3· Harmony Biosciences Management, Inc.· Source

• Recruiting

  Collaboration for Down Syndrome Progress (CDP)

  NCT07625579· RTI International· Source

• Enrolling by invitation

  A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma

  NCT07338968· Phase 3· Aura Biosciences· Source

• Recruiting

  Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

  NCT07090148· Phase 1· University of Wisconsin, Madison· Source

• Recruiting

  Hearing Aid Benefit in Real-World Noisy Environments

  NCT07226167· University of Wisconsin, Madison· Source

• Recruiting

  The ORIGIN-FH Study

  NCT07470723· University of Wisconsin, Madison· Source

• Recruiting

  CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury

  NCT06840899· Phase 2· University of Wisconsin, Madison· Source

• Recruiting

  Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma

  NCT07048457· Phase 2· Yale University· Source

• Recruiting

  The AHA Oneida Study

  NCT07139132· University of Wisconsin, Madison· Source

• Recruiting

  RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

  NCT07002034· Phase 2· Reunion Neuroscience Inc· Source

• Recruiting

  A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

  NCT06966700· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Healing Tiny Minds: Rural Recovery Through Virtual and Lived Experience Care

  NCT06643598· University of Wisconsin, Madison· Source

• Recruiting

  Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.

  NCT06394869· Pacific Edge Limited· Source

• Active, not recruiting

  Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

  NCT06619236· Phase 3· Genmab· Source

• Active, not recruiting

  Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

  NCT06627179· Phase 2· Laboratoires Thea· Source

• Recruiting

  The Avenues Study: Dual Use Cessation

  NCT06474299· Phase 4· University of Wisconsin, Madison· Source

• Recruiting

  ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials

  NCT06141993· Duke University· Source

• Active, not recruiting

  An Imaging-based Quantitative Biomarker Assay for NAFLD in Children

  NCT06354491· University of Wisconsin, Madison· Source

• Recruiting

  An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

  NCT06435000· Splice Bio· Source

• Recruiting

  RESISTance Exercise for Depression Trial

  NCT06110897· University of Wisconsin, Madison· Source

• Recruiting

  MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

  NCT06128629· Phase 3· Intellia Therapeutics· Source

• Active, not recruiting

  A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

  NCT06007690· Phase 3· Aura Biosciences· Source

• Active, not recruiting

  SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening

  NCT06120205· Teal Health, Inc.· Source

• Active, not recruiting

  Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

  NCT05782907· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

  NCT05904886· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

  NCT05589714· Jaeb Center for Health Research· Source

• Active, not recruiting

  A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma

  NCT04485949· Phase 2· Imvax· Source

• Recruiting

  A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

  NCT05723198· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

  NCT05566795· Phase 3· Day One Biopharmaceuticals, Inc.· Source

• Recruiting

  ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

  NCT05580562· Phase 3· Jazz Pharmaceuticals· Source

• Recruiting

  A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  NCT05592626· Phase 1/2· Marengo Therapeutics, Inc.· Source

• Recruiting

  Combined Electric and Acoustic Hearing (EAS) in Children and Adults

  NCT05923203· Hearts for Hearing· Source

• Enrolling by invitation

  An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

  NCT05667493· Phase 3· Ionis Pharmaceuticals, Inc.· Source

• Active, not recruiting

  Development of a Self-collection Device for Cervical Cancer Screening

  NCT05669911· Teal Health, Inc.· Source

• Active, not recruiting

  Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

  NCT05099770· Phase 3· Prokidney· Source

• Active, not recruiting

  Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

  NCT05147220· Phase 3· Novartis Pharmaceuticals· Source

• Enrolling by invitation

  Macromolecular Imaging of White and Gray Matter Pathology in Multiple Sclerosis

  NCT04415372· University of Wisconsin, Madison· Source

• Recruiting

  Clarifying the Optimal Application of SLT Therapy Trial

  NCT04967989· Phase 3· University of Pittsburgh· Source

• Active, not recruiting

  FT819 in Subjects With B-cell Malignancies

  NCT04629729· Phase 1· Fate Therapeutics· Source

• Active, not recruiting

  CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial

  NCT03455725· BioCardia, Inc.· Source

• Recruiting

  Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

  NCT04489719· University of Washington· Source

• Active, not recruiting

  Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

  NCT04562389· Phase 3· Karyopharm Therapeutics Inc· Source

Showing 50 of 69.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer4 recruiting
• Acute myeloid leukaemia3 recruiting
• Bladder cancer3 recruiting
• Chronic myeloid leukaemia3 recruiting
• Amyloidosis2 recruiting
• Asthma2 recruiting
• Cerebral palsy2 recruiting
• Colorectal cancer2 recruiting
• Congenital heart disease2 recruiting
• Hearing loss2 recruiting
• Melanoma2 recruiting
• Multiple sclerosis2 recruiting
• Myelodysplastic syndromes2 recruiting
• Stroke2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Alopecia areata1 recruiting
• ALS (motor neurone disease)1 recruiting
• Alzheimer disease1 recruiting
• Aplastic anaemia1 recruiting
• Cervical cancer1 recruiting
• Childhood cancers1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Cytomegalovirus infection1 recruiting
• Depression1 recruiting
• Down syndrome1 recruiting
• Endometrial cancer1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Glaucoma1 recruiting
• Head and neck cancer1 recruiting
• High blood pressure1 recruiting
• Hodgkin lymphoma1 recruiting
• Huntington's disease1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Lung cancer1 recruiting
• Mild cognitive impairment1 recruiting
• Multiple myeloma1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Narcolepsy1 recruiting
• Osteoarthritis1 recruiting
• Parkinson disease1 recruiting
• Retinitis pigmentosa1 recruiting
• Spinal cord injury1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  Brain Health Oneida

  NCT07080866· University of Wisconsin, Madison· Source

• Completed

  Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

  NCT06122610· Phase 1· University of Wisconsin, Madison· Source

• Withdrawn

  C-arm Cone Beam CTP Guided Cerebrovascular Interventions

  NCT05536895· University of Wisconsin, Madison· Source

• Terminated

  Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)

  NCT06042257· Phase 2· Rachel G. Greenberg, MD, MB, MHS· Source

• Recruiting

  OTC Hearing Aid and MCI

  NCT06112860· Northwestern University· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

  NCT06196879· Phase 2· Upstream Bio Inc.· Source

• Withdrawn

  SOAR-2: Intervening in Obesity Through Reduction of Dietary Branched Chain Amino Acids

  NCT04424537· Early phase 1· University of Wisconsin, Madison· Source

• Completed

  Determining the Validity of ThinkSono Guidance for Ultrasound Image Acquisition and Remote Detection

  NCT06652568· ThinkSono, Ltd.· Source

• Recruiting

  Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients

  NCT05653232· Johns Hopkins University· Source

• Completed

  Crossing the Divide: Piloting Integrated Care to Reduce Amputations Among Rural Patients With Diabetic Foot Ulcers

  NCT05203471· University of Wisconsin, Madison· Source

• Completed

  Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam

  NCT05386680· Phase 3· Novartis Pharmaceuticals· Source

• Terminated

  GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

  NCT05130255· Phase 1· Y-mAbs Therapeutics· Source

• Terminated

  A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects

  NCT05253209· Phase 3· Asklepion Pharmaceuticals, LLC· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Biogen· Source

• Completed

  Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis

  NCT04867954· University of Wisconsin, Madison· Source

• Terminated

  A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

  NCT05085366· Phase 3· ModernaTX, Inc.· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Knee Osteoarthritis Pain.

  NCT05025787· Phase 2· Maurizio Fava, MD· Source

• Completed

  Log2Lose: Incenting Weight Loss and Dietary Self-monitoring in Real-time to Improve Weight Management Among Adults With Obesity

  NCT04770909· University of Wisconsin, Madison· Source

• Completed

  Stroke Prevention in the Wisconsin Native American Population

  NCT04382963· University of Wisconsin, Madison· Source

• Completed

  A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

  NCT04772989· Phase 1· Arcus Biosciences, Inc.· Source

• Completed

  The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's

  NCT03649724· Phase 2· Weill Medical College of Cornell University· Source

• Completed

  Interventions for Patients With Alzheimer's Disease and Dysphagia

  NCT03682081· University of Wisconsin, Madison· Source

• Completed

  Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

  NCT04423718· Phase 3· Bayer· Source

• Completed

  Fostering MAT Use in Justice Populations

  NCT04363320· University of Wisconsin, Madison· Source

• Completed

  CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

  NCT04136171· Phase 3· Ionis Pharmaceuticals, Inc.· Source

• Recruiting

  Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

  NCT04278404· Duke University· Source

• Completed

  Coordinated, Collaborative, Comprehensive, Family-based, Integrated, Technology-enabled Stroke Care

  NCT04000971· Vanderbilt University Medical Center· Source

• Terminated

  NOLA (NeuWave Observational Liver Ablation) Registry

  NCT04107766· Ethicon, Inc.· Source

• Completed

  PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

  NCT04129931· Phase 2· University of North Carolina, Chapel Hill· Source

• Completed

  AB-1002 in Patients With Class III Heart Failure

  NCT04179643· Phase 1· AskBio Inc· Source

• Completed

  Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

  NCT03904693· Phase 3· Actelion· Source

• Completed

  TRC-PAD Program: In-Clinic Trial-Ready Cohort

  NCT04004767· University of Southern California· Source

• Completed

  A Community-based Assessment of Skin Care, Allergies, and Eczema

  NCT03409367· Oregon Health and Science University· Source

• Completed

  Technical Validation of MR Biomarkers of Obesity-Associated NAFLD

  NCT03674528· University of Wisconsin, Madison· Source

• Completed

  FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer

  NCT03212170· Phase 2· University of Wisconsin, Madison· Source

• Recruiting

  PARTNER 3 Trial - Aortic Valve-in-Valve

  NCT03003299· Edwards Lifesciences· Source

• Completed

  A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease

  NCT02836574· Phase 2· Prokidney· Source

• Completed

  Structural Stability of Carotid Plaque and Symptomatology

  NCT02476396· University of Wisconsin, Madison· Source

• Completed

  RNS® System Epilepsy Post-Approval Study

  NCT02403843· NeuroPace· Source

• Completed

  PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - S3 Intermediate

  NCT03222128· Edwards Lifesciences· Source

• Completed

  Severe Asthma Research Program

  NCT01606826· Milton S. Hershey Medical Center· Source

• Completed

  PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk

  NCT01314313· Edwards Lifesciences· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Alzheimer disease510 works · 7 trials
• Asthma125 works · 6 trials
• Prostate cancer107 works · 4 trials
• Mild cognitive impairment76 works · 3 trials
• Melanoma64 works · 5 trials
• Down syndrome62 works · 3 trials
• Epilepsy60 works · 1 trial
• Kidney cancer32 works · 0 trials
• Multiple myeloma30 works · 2 trials
• Pancreatic cancer27 works · 0 trials
• Osteoporosis26 works · 0 trials
• Glaucoma24 works · 1 trial
• Type 1 diabetes24 works · 0 trials
• Narcolepsy24 works · 1 trial
• Hodgkin lymphoma23 works · 2 trials
• Autism23 works · 0 trials
• Triple-negative breast cancer20 works · 1 trial
• Lupus (SLE)20 works · 0 trials
• Cytomegalovirus infection19 works · 2 trials
• Frontotemporal dementia19 works · 0 trials
• Obstructive sleep apnoea19 works · 0 trials
• Meningioma19 works · 0 trials
• ALS (motor neurone disease)18 works · 1 trial
• Hearing loss18 works · 3 trials
• Insomnia18 works · 1 trial
• Atopic dermatitis (eczema)17 works · 2 trials
• Macular degeneration17 works · 2 trials
• Long COVID and ME/CFS17 works · 0 trials
• Neuroblastoma16 works · 1 trial
• Head and neck cancer15 works · 1 trial